Gujarat Magazine

Advanced Ovarian Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

 Breaking News
  • No posts were found

Advanced Ovarian Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

June 24
22:55 2024
Advanced Ovarian Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Advanced Ovarian Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Ovarian Cancer Research. Learn more about our innovative pipeline today! @ Advanced Ovarian Cancer Pipeline Outlook

Key Takeaways from the Advanced Ovarian Cancer Pipeline Report

  • June 2024:- AstraZeneca– A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation. To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
  • June 2024:- Incyte Corporation– A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors. This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
  • June 2024:- Valerio Therapeutics- This is a phase 1/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and PK/PD of VIO-01 alone or in combination with other anti-cancer therapies in select participants with advanced HRRm or HRD+ solid tumors (i.e. BRCA1/2 mutated breast cancer, HRR mutated prostate cancer) or HRRm/HRD+/HRP (phase 1 only) recurrent ovarian cancer.
  • June 2024:- Imunon– Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
  • DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment.
  • The leading Advanced Ovarian Cancer Companies such as OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc., and others.
  • Promising Advanced Ovarian Cancer Therapies such as AST-201, Paclitaxel, Carboplatin, Bevacizumab, Olaparib, 2X-121, SC0191, and others.

Stay informed about the cutting-edge advancements in Advanced Ovarian Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Ovarian Cancer Clinical Trials Assessment

Advanced Ovarian Cancer Emerging Drugs Profile

  • Oregovomab: OncoQuest

Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen.

  • Stenoparib: Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.

  • DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2).

Learn more about Advanced Ovarian Cancer Drugs opportunities in our groundbreaking Advanced Ovarian Cancer Research and development projects @ Advanced Ovarian Cancer Unmet Needs

Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

Advanced Ovarian Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Advanced Ovarian Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspectives

Advanced Ovarian Cancer Companies and Therapies

  • Aston Sci Inc.:- AST-201
  • AstraZeneca:- Bevacizumab
  • Allarity Therapeutics: 2X-121
  • Tesaro Inc:- Niraparib
  • Jacobio Pharmaceuticals Co., Ltd.: JAB-8263

Scope of the Advanced Ovarian Cancer Pipeline Report

  • Coverage- Global
  • Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc., and others.
  • Advanced Ovarian Cancer Therapies- AST-201, Paclitaxel, Carboplatin, Bevacizumab, Olaparib, 2X-121, SC0191, and others.
  • Advanced Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Ovarian Cancer Pipeline on our website @ Advanced Ovarian Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced ovarian cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced ovarian cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Advanced ovarian cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Oregovomab: OncoQuest
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Stenoparib – Allarity Therapeutics
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. DS-6000a: Daiichi Sankyo Company
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Advanced ovarian cancer Key Companies
  23. Advanced ovarian cancer Key Products
  24. Advanced ovarian cancer- Unmet Needs
  25. Advanced ovarian cancer- Market Drivers and Barriers
  26. Advanced ovarian cancer- Future Perspectives and Conclusion
  27. Advanced ovarian cancer Analyst Views
  28. Advanced ovarian cancer Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/